Northeast Investment Management Sells 974 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Northeast Investment Management sold 974 shares of Thermo Fisher Scientific, reducing its stake by 1.1% to 84,986 shares, which are valued at approximately $34.5 million.
• CEO Marc N. Casper and EVP Gianluca Pettiti recently sold shares, with Casper's sale resulting in a 0.35% decrease in his ownership, now totaling around $56.9 million.
• Analysts have mixed sentiments on the stock, with recent forecasts leading to varying price targets ranging from $565.00 to $590.00, maintaining a consensus rating of "Moderate Buy."

Northeast Investment Management decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 84,986 shares of the medical research company's stock after selling 974 shares during the period. Thermo Fisher Scientific comprises about 1.5% of Northeast Investment Management's investment portfolio, making the stock its 19th biggest position. Northeast Investment Management's holdings in Thermo Fisher Scientific were worth $34,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC increased its holdings in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $31,000. IMA Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at $37,000. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on TMO shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Barclays increased their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a research report on Thursday, October 2nd. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target on the stock in a report on Friday, July 11th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $589.10.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $539.05 on Friday. The firm has a market cap of $203.55 billion, a PE ratio of 31.18, a price-to-earnings-growth ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company's fifty day simple moving average is $495.74 and its two-hundred day simple moving average is $449.13.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the company posted $5.37 EPS. The company's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.